REGN

Regeneron Pharmaceuticals
D

REGN

Arincen80/100B

If you had invested in Regeneron Pharmaceuticals ago, it would be worth $2,345 today, against $3,836 in SPY and $5,891 in QQQ.

ArincenArincen ScoreBeta

80/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

Regeneron Pharmaceuticals key facts

Style
Growth stock · 6.7/10Growth 6.7 · Value 5.0 · Dividend 1.0
Day range
919.82 – 947.71
52-week range
591.52 – 991.73
Market capitalization
95.50B USD
P/E
19.65
PEG ratio
1.13
EPS
46.98
Div Yield
0.41%
EPS growth forecast (FY2026)
+53.7%
Volume
34,930
Beta
0.24
ESG score
49.7/100Environment 47 · Social 48 · Governance 54
Sector
Healthcare
Industry
Biotechnology
CEO
Leonard S. Schleifer
Employees
15K
IPO date
2 Apr 1991

Regeneron Pharmaceuticals earnings

Next earnings · Q4 FY2026
EPS estimate
25.80 USD
Revenue estimate
5.85B USD
Last quarter · Q3 FY2026
EPS20.07Beat +21.6%Revenue5.12BBeat +11.6%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q2 FY202820.84———5.43B———
Q1 FY202817.86——+12.07%4.90B——+6.42%
Q1 FY202715.94——+68.33%4.60B——+27.71%
Q4 FY202625.80——+125.52%5.85B——+50.66%
Q3 FY202616.5120.07+21.56%+69.65%4.58B5.12B+11.59%+36.27%
Q2 FY202610.1614.29+40.65%+10.86%3.82B4.29B+12.40%+16.73%
Q1 FY20268.919.47+6.29%+15.21%3.48B3.61B+3.59%+19.04%
Q4 FY202510.7411.44+6.52%-5.22%3.81B3.88B+1.93%+2.51%
Q3 FY20259.6511.83+22.59%-5.06%3.59B3.75B+4.51%+0.90%
Q2 FY20258.4312.89+52.91%+11.51%3.29B3.68B+11.78%+3.62%

Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved

Regeneron Pharmaceuticals analyst forecast

12-month price target
937.29 USD
+1.51%

Analysts' 1-year price targets range from 756.00 to 1,100.00, with an average of 937.29.

Past year
1-year forecast
Strong sellStrong buy
Buy
25 ratings
Buy
17
Hold
8
Sell
0

12-month price target

Highest target1,100.00
Average target937.29
Lowest target756.00
Current price923.33

Regeneron Pharmaceuticals valuation

Price to earnings ratio (TTM)
19.65
Forward P/E (FY2026)
13.53
Price to sales (TTM)
5.65
Price to book
2.85
EV / EBITDA (TTM)
14.66

Capital structure

Market capitalization
95.50B USD
+
Total debt
2.71B USD
−
Cash and short-term investments
9.30B USD
=
Enterprise value
88.91B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)11.97————
FY2027 (est.)13.0211.97———
FY2026 (est.)13.5313.02———
Now (TTM)19.6513.085.652.8514.66
FY202517.9211.325.632.5813.81
FY202417.4216.395.412.6214.49
FY202323.7119.587.143.6119.96
FY202217.8116.946.353.4114.61
FY20218.2712.394.153.566.88

Regeneron Pharmaceuticals against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Moderna, Vertex Pharmaceuticals, Revolution Medicines, Insmed, United Therapeutics, and Incyte, the US Biotechnology companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Above its median19.7
    7.430.5
  • Gross marginAt its median85.4%
    82.9%86.1%
    Against its peers: 5 of 7Peers' median 87.1%
  • Operating marginLowest in 5 years24.9%
    24.9%55.7%
    Against its peers: 4 of 7Peers' median -66.0%
  • Net marginAt its median31.4%
    30.1%50.2%
    Against its peers: 3 of 7Peers' median -60.1%
  • Return on equityLowest in 5 years14.4%
    14.4%43.0%
    Against its peers: 4 of 7Peers' median -2.5%
  • Free cash flow marginBelow its median28.4%
    25.8%40.6%
    Against its peers: 2 of 7Peers' median -39.9%
  • Revenue growthBelow its median1.0%
    -24.3%89.1%
    Against its peers: 5 of 7Peers' median 9.8%
  • EPS growthAt its median8.2%
    -46.9%135.8%
    Against its peers: 3 of 3Peers' median 2,093.2%
  • Debt to EBITDABelow its median0.47×
    0.28×0.58×
    Against its peers: 4 of 4Peers' median 0.02×
  • Current ratioBelow its median4.13
    3.565.69
    Against its peers: 3 of 7Peers' median 3.57

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Regeneron Pharmaceuticals growth and profitability

Revenue (TTM)
16.90B USD
Net income (TTM)
4.82B USD
Gross margin
85.77%
Operating margin
28.79%
Net margin
28.51%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202514.34B+0.99%4.50B+2.09%85.35%24.95%31.41%5.82B+9.41%
FY202414.20B+8.27%4.41B+11.61%86.13%28.10%31.07%5.32B+13.31%
FY202313.12B+7.76%3.95B-8.87%82.89%30.85%30.14%4.69B-10.77%
FY202212.17B-24.26%4.34B-46.28%85.99%38.93%35.64%5.26B-45.61%
FY202116.07B+89.14%8.08B+129.86%83.05%55.67%50.25%9.67B+135.65%

Regeneron Pharmaceuticals revenue breakdown

By product

FY2025
Collaboration Revenue: 51.1%Product: 44.0%Product and Service, Other: 4.9%51.1%Collaboration Revenue44.0%Product4.9%Product and Service, Other
SegmentRevenueShare of revenueChange on the year
Collaboration Revenue7.33B51.1%+21.0%
Product6.31B44.0%-17.3%
Product and Service, Other702.60M4.9%+36.4%

How Regeneron Pharmaceuticals makes its money

Collaboration Revenue7.33B 51.1%
Product6.31B 44.0%
Product and Service, Other702.60M 4.9%
Revenue14.34B 100.0%
Cost of revenue2.10B 14.6%
Gross profit12.24B 85.4%
Research and development5.85B 40.8%
Selling and administration2.70B 18.8%
Other operating expenses114.10M 0.8%
Operating income3.58B 24.9%
Tax725.80M 5.1%
Net income4.50B 31.4%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

Regeneron Pharmaceuticals dividends

Annual dividend
3.76 USD
Dividend yield (indicated)
0.41%
Payout ratio
8.00%
Years of dividend growth
1
Frequency
Quarterly
Next payment
0.94 USD
Last ex-dividend date
20 Nov 2026
Next payment date
3 Dec 2026

Dividends per share

Year2025
Dividends per share3.52

Regeneron Pharmaceuticals financial health

Cash and short-term investments
9.30B USD
Total debt
2.71B USD
Net cash
6.59B USD
Free cash flow (TTM)
3.83B USD
Current ratio
3.35
Debt to equity
0.08
Piotroski score
7 / 9
Altman Z-score
7.85

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20258.61B2.71B4.08B
FY20249.01B2.70B3.66B
FY202310.84B2.70B3.88B
FY20227.74B2.70B4.42B
FY20215.69B2.70B6.53B

Regeneron Pharmaceuticals ownership

Institutions
70.12%
Institutional holders
1,260 (-142)
Free float
96.25%

Who owns the shares

Institutions 70.1% Others 29.9%
As of 30 Sept 2026

Shares free to trade

Free float 99.55M shares ·96.2% Closely held 3.88M shares ·3.8%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q4 202605772.03K151.42K
Q3 20260620.17K37.93K
Q2 20260210.00200.00
Q1 202604927.43K9.51K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025104.60M108.60M-5.65%
FY2024107.90M115.10M+1.23%
FY2023106.70M113.70M+0.18%
FY2022107.10M113.50M+1.16%
FY2021105.70M112.20M-2.52%

Source: Financial Modeling PrepVerified against SEC filings

Related Instruments

Title: Regeneron Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Regeneron Pharmaceuticals Inc. is an integrated biotechnology firm. The company was founded in 1988 and is headquartered in Tarrytown, New York. It develops, manufactures and sells medicines for serious conditions such as eye diseases, allergy and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and more. Its product line includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST and ZALTRAP. The company was founded by Alfred G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988.

Common questions about Regeneron Pharmaceuticals stock